{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Stable+%28MSS%29+Colorectal+Adenocarcinomas", "query": { "condition": "Microsatellite Stable (MSS) Colorectal Adenocarcinomas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Stable+%28MSS%29+Colorectal+Adenocarcinomas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:15:54.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04362839", "title": "Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colon Adenocarcinoma", "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2020-05-27", "completion_date": "2025-12-11", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04362839" }, { "nct_id": "NCT03800602", "title": "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage IVC Colorectal Cancer", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-01-15", "completion_date": "2021-09-04", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800602" }, { "nct_id": "NCT06784947", "title": "Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable (MSS) Colorectal Cancer (CRC)", "Metastatic Colorectal Cancer (CRC)", "Colorectal Cancer Stage IV" ], "interventions": [ { "name": "Pre-Treatment Biopsy", "type": "PROCEDURE" }, { "name": "On-Treatment Biopsy", "type": "PROCEDURE" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2025-03-25", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784947" }, { "nct_id": "NCT04599140", "title": "SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "CXCR1/2 Inhibitor SX-682", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2020-10-14", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599140" }, { "nct_id": "NCT04044430", "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer", "Stage III Colorectal Cancer", "Stage III Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Colorectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Colorectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Colorectal Cancer", "Stage IIIC Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Colorectal Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Rectal Cancer", "Stage IVC Colon Cancer", "Stage IVC Colorectal Cancer", "Stage IVC Rectal Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-31", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044430" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT03549000", "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Triple Negative Breast Cancer (TNBC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer Microsatellite Stable (MSS)", "Ovarian Cancer", "Renal Cell Carcinoma (RCC)", "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "NZV930", "type": "OTHER" }, { "name": "PDR001", "type": "OTHER" }, { "name": "NIR178", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2018-07-18", "completion_date": "2022-10-17", "has_results": false, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 2, "location_summary": "Tampa, Florida • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03549000" }, { "nct_id": "NCT04301011", "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Microsatellite Stable Colorectal Cancer", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Cervical Cancer", "Melanoma (Skin)", "Cutaneous Squamous Cell Carcinoma", "Mesothelioma", "Renal Cell Carcinoma", "Oropharynx Cancer" ], "interventions": [ { "name": "TBio-6517", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Turnstone Biologics, Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-06-02", "completion_date": "2023-01-23", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04301011" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Gastric/Gastroesophageal Junction Adenocarcinoma", "Microsatellite Stable Colorectal Cancer", "Non-Small-Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Carcinoma, Renal Cell", "Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Melanoma", "Ovarian Neoplasms", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "BMS-986340", "type": "DRUG" }, { "name": "BMS-936558-01", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 949, "start_date": "2021-05-27", "completion_date": "2028-07-07", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T02:15:54.397Z", "location_count": 11, "location_summary": "Clovis, California • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895709" } ] }